drug · antibody
trastuzumab biosimilar
pre_registrationupdated 3mo agoby EirGenix Inc🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 8- tagApproval38 co-mentions · 19 sources
- drugtrastuzumab emtansine28 co-mentions · 14 sources
- drugKADCYLA28 co-mentions · 14 sources
- drugtrastuzumab21 co-mentions · 21 sources
- drugONTRUZANT10 co-mentions · 5 sources
- companySamsung Bioepis Co Ltd5 co-mentions · 5 sources
- tagBreast Cancer2 co-mentions · 1 sources
- tagOncology2 co-mentions · 1 sources
Antibody drug with a maximum clinical stage of Approval (across all indications), with 8 approved and 28 investigational indications.
indications
indications
Breast Cancer
targets
Receptor tyrosine-protein kinase erbB-2
all catalysts(0)
nothing on the calendar yet
Trials studying trastuzumab biosimilar
- phase2Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
- phase1A Study to Compare PK, Immunogenicity and Safety of Trastuzumab of Incepta Pharmaceuticals Ltd With Trastuzumab (Roche)
- —A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC
News(9)
- A Spanish biotech banks $87M to make differentiated ADCsOna Therapeutics, a Barcelona-based drugmaker, is developing next-generation drugs it says could help patients with advanced forms of breast and colorectal cancers.biopharma_dive · 2mo ago
- Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast CancerSacituzumab govitecan plus trastuzumab following T-DXd did not meet the primary end point of the SATEEN trial in HER2+ metastatic breast cancer.onclive · 3mo ago
- Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ASCO 2026.onclive · 3mo ago
- Neoadjuvant T-DXd Followed by THP Improves RCB in HER2+ Breast CancerTreatment with neoadjuvant T-DXd followed by THP resulted in lower RCB vs ddAC-THP in patients with high-risk, HER2-positive early-stage breast cancer.onclive · 3mo ago
- ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You GoBreast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.onclive · 3mo ago
- Breast Cancer Experts Preview Abstracts to Watch at the 2026 ESMO Breast Cancer CongressExperts in a range of breast cancer subtypes highlight research data being presented at the 2026 ESMO Breast Cancer Congress.onclive · 3mo ago
- Sanofi’s immunology reckoning; Lilly acquires in vivo CAR-T biotech; RevMed’s ‘Herceptin moment’; and moreWelcome back to another edition of Endpoints Weekly! We’re doing a little bit of celebrating here at Endpoints, as we took home three Neal Awards, which recognize excellence in B2B journalism. The ...endpoints · 3mo ago
- Roche, facing biosimilar threats, puts faith in new cancer and obesity drugsOn a conference call, executives claimed that a closely watched breast cancer pill and portfolio of weight loss medicines could bank more than $9 billion annually.biopharma_dive · 3mo ago
- Roche says its investigational breast cancer pill could outsell HerceptinRoche still has high sales hopes for its breast cancer pill giredestrant despite the drug’s failure in a first-line trial earlier this year. CEO Thomas Schinecker said Thursday that the drug could ...endpoints · 3mo ago
Data sources
last refreshed 35m ago
Found something off?
comments(0)
5-min edit window · permanent after that